ArticleBriefings in bioinformatics2026
Mitigating negative data bias to enhance TCR-epitope binding and residue interaction prediction.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HLA-II Expression Marks Activated and Clonally Expanded CD8International journal of molecular sciences · 2026Article
- Bridging model performance and clinical utility in T cell receptor-epitope binding prediction.Clinical and translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Accurate prediction of the binding specificity between T-cell receptors (TCRs) and epitopes, along with the elucidation of their molecular interaction mechanisms, is pivotal for advancing immunotherapy and vaccine development. In this study, we propose a negative dataset construction strategy based on region-directed random mutations as an effective complement to traditional negative sampling methods. This strategy preserves the conserved amino acid motifs encoded by the V and J gene segments of the CDR3$\beta$ sequence while introducing key residue mutations within the central junctional region. By constructing hard negatives, this approach encourages the model to capture more discriminative TCR-epitope binding features. Based on this optimized dataset, we developed TranTCR, a computational framework comprising two models: TranTCR-bind, which focuses on global sequence-level binding probability prediction, and TranTCR-map, which leverages transfer learning to translate global binding knowledge into fine-grained characterizations of residue-level interactions, such as inter-residue distances and contact scores. Experimental results demonstrate that TranTCR-bind exhibits superior predictive performance and generalization robustness across various negative sampling protocols. Furthermore, TranTCR-map utilizes attention mechanisms to deeply resolve complex inter-amino acid associations, enabling the identification of latent binding patterns and the revelation of TCR cross-reactivity characteristics. This study provides an efficient computational tool for the high-throughput screening of TCR repertoires and the digital characterization of immune recognition mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.